PT936923E - Supressao de tnfalfa e il-12 em terapia - Google Patents

Supressao de tnfalfa e il-12 em terapia

Info

Publication number
PT936923E
PT936923E PT97912367T PT97912367T PT936923E PT 936923 E PT936923 E PT 936923E PT 97912367 T PT97912367 T PT 97912367T PT 97912367 T PT97912367 T PT 97912367T PT 936923 E PT936923 E PT 936923E
Authority
PT
Portugal
Prior art keywords
tnf
tnfalfa
blending
therapy
disclosed
Prior art date
Application number
PT97912367T
Other languages
English (en)
Inventor
Ravinder Nath Maini
Marc Feldmann
Anne-Marie Aline Miche Malfait
Debra Maree Butler
Fionula Mary Brennan
Original Assignee
Kennedy Inst Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kennedy Inst Of Rheumatology filed Critical Kennedy Inst Of Rheumatology
Publication of PT936923E publication Critical patent/PT936923E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97912367T 1996-11-15 1997-11-17 Supressao de tnfalfa e il-12 em terapia PT936923E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74997996A 1996-11-15 1996-11-15

Publications (1)

Publication Number Publication Date
PT936923E true PT936923E (pt) 2004-04-30

Family

ID=25016019

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97912367T PT936923E (pt) 1996-11-15 1997-11-17 Supressao de tnfalfa e il-12 em terapia

Country Status (9)

Country Link
US (1) US20070178099A1 (pt)
EP (1) EP0936923B1 (pt)
AT (1) ATE256476T1 (pt)
AU (1) AU4959997A (pt)
DE (1) DE69726878T2 (pt)
DK (1) DK0936923T3 (pt)
ES (1) ES2213209T3 (pt)
PT (1) PT936923E (pt)
WO (1) WO1998022137A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
AU2612100A (en) * 1999-01-13 2000-08-01 Rockefeller University, The Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
KR100818066B1 (ko) * 1999-03-25 2008-03-31 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-１２에 결합하는 사람 항체
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE60039783D1 (de) * 1999-12-14 2008-09-18 Genentech Inc Lfa-1 antagonisten und tnf-alpha antagonisten zur
KR20070087256A (ko) * 2000-02-21 2007-08-27 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Ｉｌ-18 저해물질의 용도
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US6881407B2 (en) * 2000-08-11 2005-04-19 Ashok Amin Method for treating hepatitis
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
GB0128138D0 (en) * 2001-11-23 2002-01-16 King S College London Pharmaceutical use
US20030161828A1 (en) * 2002-02-19 2003-08-28 Abbott Gmbh & Co. Kg Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US20060210563A1 (en) * 2003-07-25 2006-09-21 Juan Lopez De Silanes Administration of anti-cytokine f(ab')2 antibody fragments
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
AU2008205512B2 (en) 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
BRPI0809209A2 (pt) 2007-03-29 2014-09-02 Abbott Lab Anticorpos il-12 anti-humanos cristalinos
TWI461210B (zh) 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
EP2346897A2 (en) * 2008-10-20 2011-07-27 Abbott Laboratories Viral inactivation during purification of antibodies
TW201030016A (en) * 2008-10-20 2010-08-16 Abbott Lab Antibodies that bind to IL-18 and methods of purifying the same
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
SG195573A1 (en) * 2008-10-20 2013-12-30 Abbott Lab Antibodies that bind to il-12 and methods of purifying the same
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US8394593B2 (en) * 2010-02-12 2013-03-12 Trudeau Institute Use of an IL-12 receptor splice variant and molecular assay to quantify expression thereof
US8877212B2 (en) 2011-02-07 2014-11-04 Trudeau Institute Use of an IL12 receptor-beta 1 splice variant to diagnose active tuberculosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
CA2106299C (en) * 1991-03-18 2001-02-06 Junming Le Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
ATE155043T1 (de) * 1992-10-08 1997-07-15 Kennedy Inst Of Rheumatology Behandlung von autoimmun- und entzundungskrankheiten
US5536657A (en) * 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
ES2255067T3 (es) * 1995-08-01 2006-06-16 F. Hoffmann-La Roche Ag Receptores para la interleucina-12 humana.

Also Published As

Publication number Publication date
ATE256476T1 (de) 2004-01-15
DK0936923T3 (da) 2004-04-26
ES2213209T3 (es) 2004-08-16
EP0936923A1 (en) 1999-08-25
AU4959997A (en) 1998-06-10
EP0936923B1 (en) 2003-12-17
DE69726878D1 (de) 2004-01-29
WO1998022137A1 (en) 1998-05-28
US20070178099A1 (en) 2007-08-02
DE69726878T2 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
PT936923E (pt) Supressao de tnfalfa e il-12 em terapia
HK1022440A1 (en) Combination therapy using a tnf binding protein for treating tnf-mediated diseases
ZA975211B (en) Compositions and methods for administering borrelia DNA.
EP0687183A4 (en) SYNERGISTIC COMPOSITION OF A CD4-BASED PROTEIN AND ANTIBODY AGAINST HIV-1, AND METHODS OF USE
ATE281840T1 (de) Behandlung von diarrhoe
PT915697E (pt) Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
DE69613689D1 (de) System zum einspritzen von zusatzstoffen in den auflaufkasten
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
ZA976181B (en) Methods of enhancing lean tissue mass and bone mineral content and compositions therefor.
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DK0760010T3 (da) Fremgangsmåder til screening for Crohn's sygdom under anvendelse af TNF-mikrosatellit-alleler
FR2611274B1 (fr) Ensemble pour la detection du sida, procede de determination des risques de sida et composition therapeutique contre cette maladie
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
SG52537A1 (en) Methods and compositions for the treatment of cell proliferation disorders
AU1187597A (en) Compositions and methods for diagnosis of mutation in the von hippel-lindau tumor suppressor gene
ZA989036B (en) Methods and compositions for treating rheumatoid arthritis.
EP0642333A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH IMMUNOLOGICAL DYSFUNCTION.
DE69928523D1 (de) Verotoxin b untereinheit zur immunisierunug
HUP0002304A2 (hu) Állatok májából kivonható fehérjék alkalmazása tumor nekrózis faktor túltermelődéssel járó kóros állapotok kezelésére használható gyógyászati készítmények előállítására
ZA97459B (en) Composition and methods for administering borrelia burgdorferi antigens.
AU1592801A (en) Methods of treating inflammatory bowel disease using cholera toxin B subunit
IT9003692A0 (it) Dispositivo per l' assemblaggio di pannelli di mobili in genere.
FR2735470B1 (fr) Nitrocetones et nitroximes, leur preparation et leur application en therapeutique